[1]中国卒中学会，中国卒中学会神经介入分会，中华预防医学会卒中. 急性缺血性卒中血管内治疗中国指南2018[J]. 中国卒中杂志，2018，13（7）：706-729.
[2]POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2019，50（12）：e344-e418[2023-04-20]. https://doi.org/10.1161/str.0000000000000211.
[3]ALEXANDROV A V，GROTTA J C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator[J]. Neurology，2002，59（6）：862-867.
[4]SAQQUR M，MOLINA C A，SALAM A，et al. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment：a multicenter transcranial Doppler study[J]. Stroke，2007，38（1）：69-74.
[5]SENERS P，HURFORD R，TISSERAND M，et al. Is Unexplained early neurological deterioration after intravenous thrombolysis associated with thrombus extension？[J]. Stroke，2017，48（2）：348-352.
[6]CHEN L，CAO S，YANG J. Argatroban plus aspirin versus aspirin in acute ischemic stroke[J]. Neurol Res，2018，40（10）：862-867.
[7]HOSOMI N，NAYA T，KOHNO M，et al. Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke[J]. J Neurol，2007，254（5）：605-612.
[8]BERRY C N，GIRARDOT C，LECOFFRE C，et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin：comparison with heparin and recombinant Hirudin[J]. Thromb Haemost，1994，72（3）：381-386.
[9]JANG I K，GOLD H K，LEINBACH R C，et al. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator[J]. Circulation research，1990，67（6）：1552-1561.
[10]MORRIS D C，ZHANG L，ZHANG Z G，et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke[J]. Stroke，2001，32（11）：2635-2640.
[11]BARRETO A D，ALEXANDROV A V，LYDEN P，et al. The argatroban and tissue-type plasminogen activator stroke study：final results of a pilot safety study [J]. Stroke，2012，43（3）：770-775.
[12]BARRETO A D，FORD G A，SHEN L，et al. Randomized，multicenter trial of ARTSS-2（argatroban with recombinant tissue plasminogen activator for acute stroke）[J]. Stroke，2017，48（6）：1608-1616.
[13]BEREKASHVILI K，SOOMRO J，SHEN L，et al. Safety and feasibility of argatroban，recombinant tissue plasminogen activator，and intra-arterial therapy in stroke（ARTSS-IA Study）[J]. J Stroke Cerebrovasc Dis，2018，27（12）：3647-3651.
[14]CHEN H S，CUI Y，ZHOU Z H，et al. Effect of
argatroban plus intravenous alteplase vs intravenous alteplase alone on neurologic function in patients with acute ischemic stroke：the ARAIS randomized clinical trial[J]. JAMA，2023，329（8）：640-650.
